Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Genentech has teamed with Microbiotica to develop tests, drug targets, and treatments for inflammatory bowel disease. Financial specifics of the deal were not disclosed, but Microbiotica could earn up to $534 million in the collaboration. Microbiotica was spun out of the Wellcome Sanger Institute in 2016 with expertise in unraveling host-microbiome interactions. It will analyze samples from patients in clinical trials of Genentech’s IBD drugs to find biomarkers that indicate a drug is working, identify novel IBD drug targets, and develop bacteria-based therapeutics.
This article has been sent to the following recipient: